Inclusion Criteria:

          -  Advanced or recurrent epithelial ovarian, fallopian tube or primary peritoneal
             carcinoma. Histologic documentation of the original primary tumor is required via the
             pathology report

          -  AR expression ≥5% by IHC. In cases where multiple blocks are available staining will
             be performed on unstained slides from 3 separate blocks. If ≥ 5% AR tumor staining is
             seen on ≥ 1 slide the tumor will be considered to be AR+.

          -  Patients with the following histologic cell types are eligible: serous adenocarcinoma,
             endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma,
             clear cell adenocarcinoma, mixed epithelial adenocarcinoma, transitional cell
             carcinoma, malignant Brenner's tumor, or adenocarcinoma not otherwise specified

          -  Measurable disease as defined by RECIST 1.1. Measurable disease is defined as at least
             one lesion that can be accurately measured in at least one dimension. Each lesion must
             be ≥10mm when measured by CT, MRI or caliper measurement by clinical exam; or ≥ 20mm
             when measured by chest x-ray. Lymph nodes must be ≥ 15mm in short axis when measured
             by CT or MRI

          -  Patients must have had one prior platinum-based chemotherapeutic regimen for
             management of primary disease

          -  Patients may have received, but are not required to have received, one or two
             additional cytotoxic regimens for management of recurrent or persistent disease

          -  Patients who have received only one prior cytotoxic regimen (platinum-based regimen
             management of primary disease), must have a platinum-free interval of less than 12
             months, or have progressed during platinum-based therapy, or have persistent disease
             after a platinum-based therapy

          -  Patients are allowed to receive, but are not required to receive, non-cytotoxic
             therapy (such as bevacizumab) as part of their primary treatment regimen.

          -  Patients are allowed to receive, but are not required to receive, non-cytotoxic
             therapy for management of recurrent or persistent disease

          -  Must be ≥ 18 years of age

          -  Karnofsky Performance Status (KPS) of ≥ 70%

          -  Life expectancy of ≥ 12 weeks Women of child-bearing potential must have a negative
             pregnancy test within 14 days prior to commencement of study treatment

          -  Women of child bearing potential must use an effective form of contraception during
             study and for at least 6 months after completion of study treatment

          -  Recovery from effects of recent surgery, radiotherapy, or chemotherapy

               -  At least 4 weeks out from their last dose of radiation therapy

               -  At least 4 weeks post-op from any major surgical procedure

               -  At least 3 weeks out from their last dose of chemotherapy and/or
                  biologic/targeted therapy

          -  No prior hormonal therapy for treatment of cancer within the past 21 days

          -  Absence of any psychological, familial, sociological or geographic condition that
             would potentially hamper compliance with the study protocol

          -  Prior use of or participation in a clinical trial evaluating and agent that either
             blocks androgen synthesis (e.g. abiraterone acetate, TAK-700, TAK-683, TAK-448) or
             targets the AR (e.g., bicalutamide, BMS-641988) (patients who are known to have only
             received placebo in these studies are eligible)

          -  Laboratory Test Findings performed within 14 days prior to initiation of study drug
             showing:

        Bone marrow function:

        Absolute neutrophil count (ANC) ≥ 1,000/mcL Platelets ≥ 100,000/mcL Hemoglobin ≥ 8 g/dL o
        Renal function: Creatinine ≤ 1.5 x ULN

        o Hepatic function: Bilirubin ≤ 1.5 x ULN AST and ALT ≤ 2.5 x ULN

          -  Resolution of all acute toxic effects of prior therapy to NCI CTCAE (Version 4.0)
             Grade ≤ 1, with the exception of unresolved Grade 2 neuropathy and Grade 2 alopecia,
             which are allowed

          -  Patients must be able to swallow tablets whole, without crushing

        Exclusion Criteria:

          -  A history of another invasive malignancy (other than non-melanoma skin cancer or
             curatively treated in situ carcinoma) with evidence of disease within the past 3 years

          -  Use of a medication known to lower the seizure threshold within 28 days of first dose
             of study drug

          -  Known brain metastasis

          -  History of seizure

          -  Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95mmHg) despite
             medical treatment. Patients with a history of hypertension are allowed provided blood
             pressure is controlled by anti-hypertensive treatment.

          -  Clinically significant heart disease as evidenced by myocardial infarction or arterial
             thrombotic event within the past 6 months, severe or unstable angina, or New York
             Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction
             measurement of < 50% at baseline

          -  Refractory nausea and vomiting, requirement for parenteral hydration and/or nutrition,
             drainage gastrostomy tube, malabsorption, external biliary shunt, or significant small
             bowel resection that would preclude adequate study drug absorption

          -  Anticipated or ongoing administration of anti-cancer therapies other than those
             administered in this study